The Life Sciences team advised Schrödinger, Inc. on a collaboration and license agreement with Bristol Myers Squibb to discover, develop, and commercialize therapeutics in multiple disease areas. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods.
The multi-year collaboration will combine Schrödinger’s leading physics-based computational software platform and drug discovery capabilities with Bristol Myers Squibb's expertise in development and commercialization to advance small molecule therapeutics for targets in oncology, immunology, and neurology.
Under the terms of the agreement, Bristol Myers Squibb will pay Schrödinger $55 million upfront, and Schrödinger will also be eligible to receive up to $2.7 billion in preclinical, development, regulatory, and sales-based milestone payments. Additionally, Schrödinger is entitled to receive royalties on net sales of each product commercialized by Bristol Myers Squibb under the agreement.
The Goodwin team was led by Sarah Solomon and Erini Svokos.
For more details, read the press release and articles in Endpoints, FierceBiotech, and The Street.